Immunomedics enters into licensing agreement with Seattle Genetics for Sacituzumab Govitecan

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Immunomedics Inc. entered into a global licensing agreement with Seattle Genetics Inc. to develop, fund, manufacture and commercialize IMMU-132, Immunomedics’ proprietary solid tumor therapy candidate.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe

YOU MAY BE INTERESTED IN

Login